This article is more than 5 years old. Information may no longer be current.
Head-to-head comparison shows real-world accuracy differences among CGM devices
Click Here to Manage Email Alerts
ORLANDO, Fla. — Among adults with type 1 diabetes concurrently wearing three continuous glucose monitoring devices, accuracy of the devices was lower than reported in clinical studies, according to a speaker here.
Researchers found the Senseonics Eversense implantable CGM to be more accurate than the Dexcom G5 and the Abbott Freestyle Libre Pro, the professional version of the CGM, devices.
“It should be noted that the Eversense and the G5 were calibrated twice daily, and the Libre Pro is designed not to allow calibrations,” Rabab Z. Jafri, MD, a fellow in endocrinology at Massachusetts General Hospital, told Endocrine Today.
Jafri and colleagues assessed the accuracy of the three systems used by 23 participants as part of a 6-week, free-living, outpatient bionic pancreas study. Researchers compared the glucose measurements obtained with the Nova Biomedical StatStrip Xpress meter, which was used to calibrate the Eversense and G5 devices, with readings from all three CGMs when they were recorded within 5 minutes of the meter readings (n = 829 sets) and also compared a greater number of readings between the G5 and Eversense (n = 2,277 sets). The primary outcome was mean absolute relative difference. Lower mean absolute relative difference indicates greater accuracy.
Among the three systems, the Eversense had the lowest mean absolute relative difference at 14.8%, with the G5 (16.3%) and the Libre Pro (18%) higher (P = .004). The Eversense again had a lower mean absolute relative difference than the G5 in a comparison between the two (15.1% vs. 16.9%; P = .008).
“We’ve previously shown that the Dexcom G5 is sufficiently accurate to provide the input to the bionic pancreas,” Jafri said. “This data suggests that the Senseonics Eversense is likewise sufficiently accurate to provide the input to the bionic pancreas devices in future studies.” – by Jill Rollet
Reference:
Jafri RZ, et al. 14-OR. Presented at: American Diabetes Association 78th Scientific Sessions; June 22-26, 2018; Orlando, Fla.
Disclosures: Jafri reports no relevant financial disclosures. Please see the abstract for all other authors’ relevant financial disclosures.
Perspective
Back to Top
Anne L. Peters, MD
The Eversense XL implantable sensor is an interesting new approach to continuous glucose monitoring in patients with type 1 diabetes. Clinically, it takes away the need for reinsertion every 10 days and because it is under the skin it is much less likely to be dislodged. A transmitter is worn to send the signal to a receiver, but this is simply placed on the surface of the skin and can be easily removed. The accuracy is good, and was shown to be as accurate as currently available devices, although it does require calibration (which the Dexcom G6 and the Libre do not). Some patients will prefer this type of continuous glucose monitoring while others will choose other options. This expands the options for patients, which is a benefit, but all of these devices need to be coupled with education and follow-up so patients can use them optimally.
Click Here to Manage Email Alerts